期刊文献+

猪腹泻大肠杆菌LTa(R210G)和LTb原核表达及其在小鼠的免疫反应

Prokaryotic Expression of Ecoli Heat-labile Enterotoxin LTa and LTb and Its Immunogenenity in Mice
下载PDF
导出
摘要 大肠杆菌不耐热性肠毒素(LT)具有免疫增强作用,是良好的免疫佐剂。为了更好的研究其免疫增强效果,本研究将LT的两个亚基LTa(R210G)和LTb克隆到pGST中,原核表达LTa(R210G)和LTb,经Western-blotting分析,表达蛋白具有免疫原性。对表达蛋白进行大量纯化后,以卵清蛋白为模式蛋白(OVA)为模式蛋白,免疫小鼠,ELISA结果表明,OVA+LTa(R210G)佐剂组小鼠的抗体滴度最高,OVA+LTb和OVA+LTa+LT组抗体滴度相似,高于OVA+氢氧化铝组,而OVA+氢氧化铝组高于无佐剂OVA组。因此,LTa(R210G)和LTb具有良好的免疫增强作用,是一种极有希望的免疫佐剂。 Ecoli heat-labile enterotoxin is a best immune adjuvant for its immunic enhancement. In order to study the effect of its immunic enhaneement,pGST-LTa(R210G) and pGST-LTb was constructed and expressed,the result of west- era-blotting showed the recombinant protein of GST-LTa(R21OG) and GST-LTb had good biological activities analogy to LT positive sera from pigs. We immunized mice with Ovalbumin,using GST-LTa(R210G) and GST-LTb as immunoadju- vant, and aluminum hydroxide adjuvant as controls. GST-LTa(R210G) showed the capability to remarkably increase the level of antibody against ovalbumin when comparing with those mice without any immunoadjuvant, and which was even higher than that of aluminum hydroxide adjuvant, LTb and LTa (R210G) plus LT adjuvant. LTb and LTa (R210G) plus LT adjuvant had the same level of antibody against Ovalbumin. Therefore, LTh and LTa (R210G) can become a new type of immunoadjuvant in future.
出处 《华北农学报》 CSCD 北大核心 2009年第B08期265-269,共5页 Acta Agriculturae Boreali-Sinica
基金 浙江省科技计划项目(2006C22049)
关键词 大肠杆菌不耐热性肠毒素 LTa和LTb 原核表达 免疫反应 Ecoli heat-labile enterotoxin LTa and LTb Prokaryotic expression Immunogenecity
  • 相关文献

参考文献8

  • 1Yamamoto T, Tamura T, Yokota T. Primary structure of heatlabile enterotoxin produced by Escherichia coli pathogenic for humans[ J]. J Biol Chem, 1984,259 : 5037 - 5044.
  • 2Girard F, Pery P, Naciri M, et al. Adjuvant effect of cholera toxin on systemic and mucosal immune responses in chickens infected with E. tenella or given recombinant parasitic antigen pews[J]. Vaccine, 1999,17:1516 - 1524.
  • 3萨姆布鲁克J 弗里奇EF 曼尼阿蒂斯T.分子克隆实验指南(第二版)[M].北京:科学出版社,1999.343-367.
  • 4Ryan E J, Daly L M, Mills K H G. Immunomodulators and delivery systems for vaccination by mucosal mutes [ J ]. Trends Biotechnol Rev, 2001,9 : 293 - 304.
  • 5Williams N A. Immune modulation by the cholera-like enterotoxin B-subunits: from adjuvant to immunotherapeutic [ J ]. Int J Med Microbiol,2000,290 (4 - 5) ,447 - 453.
  • 6Fingerut E, Gutter B, Goldway M, et al. Subunit of E. coli enterotoxin as adjuvant and carrier in oral and skin vaccination[J]. J Vet Immunol Immunopathol, 2006, 15,112 (3 - 4) :253 - 63.
  • 7夏肖萍,胡野,严杰.大肠杆菌重组LTKA63突变体和LTB黏膜免疫佐剂活性的研究[J].中华微生物学和免疫学杂志,2006,26(4):354-359. 被引量:3
  • 8De Haan L, Verweij W R, Agsteribbe E, et al. Mucosal immunogenicity and adjuvant activity of the recombinant a subunit of the Escherichia coli heat-labile enterotoxin[ J]. Immunol, 1999,97:706 - 713.

二级参考文献22

  • 1Pizza M,Giuliani MM,Fontana MR,et al.Mucosal vaccines:non-toxin derivatives of LT and CT as mucosal adjuvants.Vaccine,2001,19:2534-2541.
  • 2Magagnoli C,Manetti R,Fontana MR,et al.Mutations in the A subunit affect yield,and protease sensitivity of nontoxic derivatives of heat-labile enterotoxin.Infect Immun,1996,64:5434-5438.
  • 3Giudice GD,Podda A,Rappuoli R.What are the limits of adjuvanticity?Vaccine,2002,20:S38-S41.
  • 4Sambrook J,Fritsch EF,Maniatis T.Molecular cloning,a laboratory manual.2nd edition.New York:Cold Spring Harbor Laboratory Press.1989,pp1.21-1.52,2.60-2.80,7.3-7.35,9.14-9.22.
  • 5De Haan L,Holtrop M,Verweij WR,et al.Mucesal immunogenicity of the Escherchia coli heat-labile enterotoxin:role of the A subunit.Vaccine,1996,14:260-266.
  • 6Lewis SM,Osei-Bimpong A.Haemoglobinometry in general practice.Clin L8ab Haematol,2003,25:343-346.
  • 7De Haan L,Verweij WR,Agsteribbe E,et al.Mucosal immunogenicity and adjuvant activiy of the recombinant A subunit of the Escherichia coli heat-labile enterotoxin.Immunol,1999,97:706-713.
  • 8De Haan L,Verweij WR,Holtrop M,et al.Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Esherichia coli heat-labile toxin induce IgA-or IgG-mediated protective mucosal immunity.Vaccine,2001,19:2898-2907.
  • 9Kotloff KL,Sztein MB,Wasserman SS,et al.Safety and immunogenicity of oral inactivated whole-cell Hdicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection.Infect Immun,2001,69:3581-3590.
  • 10Cheng E,Freytag LC,Clemants JD.The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT).Vaccine,2000,18:38-49.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部